Stocktoria
VivoSim Labs, INC. VIVS
VivoSim Labs, INC. (VIVS) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $131,000 at a -10567.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VIVS | VivoSim Labs, INC. | 2/9 | — | — | — |
| ZIVO | Zivo Bioscience, Inc. | 4/9 | — | — | — |
| ATYR | aTYR PHARMA INC | 1/9 | -19.49 | — | — |
| INMB | Inmune Bio, Inc. | 3/9 | — | — | — |
| ENTX | Entera Bio Ltd. | 2/9 | — | — | — |
| SNTI | Senti Biosciences Holdings, Inc. | 2/9 | — | — | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
About VivoSim Labs, INC.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FAQ
Is VIVS financially healthy?
VivoSim Labs, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does VIVS pay a dividend?
No, VivoSim Labs, INC. does not currently pay a dividend.
How profitable is VIVS?
In FY2025, VivoSim Labs, INC. had a net margin of -10567.2%.
Is VIVS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VivoSim Labs, INC.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-03-31. Facts plus Stocktoria's own computed scores — not investment advice.